Patients with rheumatoid arthritis (RA) had a 46% higher risk for venous thromboembolism (VTE) than matched control individuals, with an elevated risk persisting across all age groups, BMI categories, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...

Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha ...

Rheumatoid arthritis (RA) is more than just joint pain—it’s a chronic autoimmune disease that affects millions of people worldwide. However, misconceptions about the condition often delay diagnosis ...

You’ve no doubt heard that staying hydrated is essential for overall health. But if you have rheumatoid arthritis (RA), consuming enough fluids is important for maintaining joints and feeling your ...

It’s a disease that affects one in five Canadians, is a leading cause of disability, and costs the healthcare system billions, yet experts say arthritis remains one of the most misunderstood chronic ...

Rosnilimab, a selective depleter of pathogenic T cells, is a potential game changer for the treatment of moderate-to-severe rheumatoid arthritis (RA). In a new Phase 2b clinical trial, rosnilimab ...

New Delhi: Researchers have identified changes in the gut microbiome makeup that lead to the onset of rheumatoid arthritis, providing a window of opportunity for targeted treatments. Researchers from ...

Nipocalimab combo therapy showed no added efficacy over anti-TNFα treatment in the Phase 2a trial. Johnson & Johnson ended the RA study but sees over $5 billion in potential for nipocalimab. Get a ...

NEW HYDE PARK, N.Y. & VALENCIA, Calif.--(BUSINESS WIRE)--Northwell Health and SetPoint Medical today announced that Northwell is the first health system to provide the recent U.S. Food and Drug ...